NRLE FORM - 11

La Salle University
College of Nursing
Ozamiz City

DRUG STUDY
DRUG NAME ROUTE/DOSAGE/ INDICATION MECHANISM OF CONTRAINDICATION SIDE EFFECTS NURSING
FREQUENCY ACTION RESPONSIBILITY/
PATIENT TEACHING
Generic Name: Prevention of nausea and Blocks the effects of Hypersensitivity; Baseline assessment:
Ondansetron PO (Adults): vomiting associated with serotonin at 5-HT3– Orally disintegrating Frequent (13%-5%):
Prevention of highly or moderately receptor sites tablets contain Anxiety, dizziness, Assess degree of nausea,
nausea/vomiting emetogenic chemotherapy. (selective antagonist) aspartame and drowsiness, headache, vomiting. Assess for
Brand Name: associated with PO: located in vagal nerve should not be fatigue, constipation, dehydration if excessive
Zofran highly-emetogenic Prevention of nausea and terminals used in patients with diarrhea, hypoxia, vomiting occurs (poor
chemotherapy—24 vomiting associated with and the chemoreceptor phenylketonuria; urinary retention. skins turgor, dry mucous
mg radiation therapy. Prevention trigger zone in the CNS. Congenital long membranes). Provide
Pharmacologic Class: 30 min prior to and treatment of QT syndrome; Occasional (4%-2%): emotional support.
chemotherapy. postoperative nausea and Concurrent use of Abdominal pain,
Selective 5-HT3 receptor vomiting. apomorphine. xerostomia, fever, Intervention:
antagonist PO (Adults and feeling of cold,
Children 11 yr): redness/pain at
Monitor ECG in pts with
Therapeutic Class: Prevention of injection site,
electrolyte
nausea/vomiting paresthesia, asthenia abnormalities, HF,
Antinausea, antiemetic associated with (loss of strength, bradyarrhythmias,
moderately energy). concurrent use of other
emetogenic medications that may
chemotherapy—8 Rare (1%): cause QT prolongation,
mg 30 min prior to Hypersensitivity reaction pts receiving high doses
chemotherapy and (rash, pruritus), blurred or frequent doses.
repeated 8 hr later; vision. Provide supportive
8 mg q 12 hr may measure. Assess mental
be status. Assess bowel
LA SALLE UNIVERSITY COLLEGE OF NURSING : Drug Study 2019
 given for 1– 2 days sounds for peristalsis.
following Monitor daily pattern of
chemotherapy. bowel activity, stool
Prevention of consistency. Record time
radiation-induced of evacuation.
nausea/vomiting—
8 mg Patient/family teaching:
1– 2 hr prior to  Relief form
radiation; may be nausea/vomiting
repeated q 8 hr, generally occurs
depending on type, shortly after drug
location, and administration.
extent of radiation.  Avoid alcohol
 Report persistent
Prevention of vomiting
postoperative  Avoid tasks that
nausea/vomiting— require
16 mg alertness, motor
1 hr before skills, until
induction of response to drug
anesthesia is established
(may cause
drowsiness,
IV (Adults): dizziness)
Prevention of
chemotherapy-
induced
nausea/vomiting—
0.15 mg/kg (max
dose 16 mg)
30 min prior to
chemotherapy,
repeated 4 and 8
hr
later.

LA SALLE UNIVERSITY COLLEGE OF NURSING : Drug Study 2019

 IM, IV (Adults):
Prevention of
postoperative
nausea/vomiting—
4 mg before
induction of
anesthesia
or postoperatively

IV (Children 6 mo–
18 yr):
Prevention of
chemotherapy-
induced
nausea/vomiting—
0.15 mg/kg
(max dose 16 mg)
30 min prior to
chemotherapy,
repeated 4 and 8
hr later.

IV (Children 1 mo–
12 yr and 40 k g):
Prevention of
postoperative
nausea/vomiting—
4 mg.

LA SALLE UNIVERSITY COLLEGE OF NURSING : Drug Study 2019

 IV (Children 1 mo–
12 yr and 40 kg):
Prevention
of postoperative
nausea/vomiting—
0.1 mg/kg

LA SALLE UNIVERSITY COLLEGE OF NURSING : Drug Study 2019

 DRUG NAME ROUTE/DOSAGE/ INDICATION MECHANISM OF CONTRAINDICATION SIDE EFFECTS NURSING
FREQUENCY ACTION RESPONSIBILITY/
PATIENT TEACHING
Generic Name: Severe pain (the 20 mg/mL oral Binds to opiate receptors in . : Hypersensitivity; Baseline assessment:
Morphine PO, Rect (Adults solution concentration the CNS. Alters the Some products Frequent:
50 kg): Usual should only be used in opioid- perception of and response contain tartrazine, Sedation, decreased B/P Pt should be in
starting dose for tolerant patients). Moderate to to painful stimuli while bisulfites, or alcohol (including orthostatic recumbent position
Brand Name: moderate to severe chronic pain in opioid- producing and should hypotension), before drug is given by
Duramorph, Infumorph severe pain in tolerant patients generalized CNS depression be avoided in patients diaphoresis, facial parenteral route. Assess
opioid-naive requiring use of daily, around- with known flushing, constipation, onset, type, location,
Pharmacologic Class: patients— the-clock long-term hypersensitivity; dizziness, drowsiness, duration of pain. Obtain
30 mg q 3– 4 hr opioid treatment and for which Acute, mild, nausea, vomiting vital signs before giving
Opioid agonist (Schedule initially or once alternative treatment intermittent, or medication. If
II) 24-hr opioid options are inadequate postoperative pain Occasional: respirations are 12/min
requirement is (extended-release). Pulmonary (extended/sustained- Allergic reaction (rash, or less (20/min or less in
Therapeutic Class: determined, edema. Pain associated with release); Significant pruritus), dyspnea, children), withhold
convert to MI. respiratory depression confusion, palpitations, medication, contact
Opioid analgesic extended-release (extended-release); termors, urinary physician. Effect of
morphine by Acute or severe retention, abdominal medication is reduced if
administering bronchial cramps, vision changes, full pain recurs before
total daily oral asthma (extended- dry mouth, eadache, next dose.
morphine dose release); Paralytic decreased appetite,
every 24 hr ileus pain/burning at
(extendedrelease) injection site. Intervention:
PO, Rect (Adults
and Children 50 Rare: Monitor vital signs 5-10
kg): Usual Paralytic ileus. min after IV
starting dose for administration, 15-30
moderate to min after SQ, IM. Be
severe pain in alert for decreased
opioidnaive respirations, B/P. Check
patients—0.3 adequate voiding.
mg/kg q 3– 4 hr Monitor daily pattern of
initially bowel activity, stool

LA SALLE UNIVERSITY COLLEGE OF NURSING : Drug Study 2019

 consistency; avoid
constipation. Initiate
IM, IV, Subcut deep breathing,
(Adults 50 kg): coughing exercises,
Usual starting particularly in those with
dose for pulmonary impairment.
moderate to Assess for clinical
severe pain in improvement; record
opioid-naive onset of pain relief.
patients—4– 10 Consult physician if pain
mg q 3– 4 hr. MI relief is not adequate.
—8– 15 mg, for
very Patient/family teaching:
severe pain  Disocmfort may
additional smaller occur with
doses may be injection.
given every  Change positions
3– 4 hr. slowly to avoid
orthostatic
IM, IV, Subcut hypotension.
(Adults and  Avoid tasks that
Children 50 kg): require
Usual starting alertness, motor
dose for skills until
moderate to response to drug
severe pain in is established.
opioid-naive  Avoid alcohol,
patients—0.05– CNS depressant.
0.2 mg/kg q 3– 4  Tolerance,
hr, dependence
maximum: 15 may occur with
mg/dose prolonged use of
high doses.
 Report
ineffective pain
control,

LA SALLE UNIVERSITY COLLEGE OF NURSING : Drug Study 2019

 constipation,
urinary
retention.

Submitted by: Submitted to:

Name of Student: Ivy Parrilla Ms. Maryvic M. Regalado, MN

Year Level: 3 Name of Clinical Instructor
Date: October 31, 2021 Date: October 31, 2021

LA SALLE UNIVERSITY COLLEGE OF NURSING : Drug Study 2019